证券代码：600998 证券简称：九州通 公告编号：临 2025-038 九州通医药集团股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》《上市公司章程指引》等法律法规、规范性文件及《公司 章程》的相关规定，九州通医药集团股份有限公司（以下简称"公司"）董事 会增加职工代表董事 1 名，由职工代表大会选举产生。 为完善公司治理结构，公司已于 2025 年 5 月 22 日召开第五届职工代表大 会第一次会议，选举吴志龙先生（简历附后）为公司第六届董事会职工代表董 事。吴志龙先生将与公司现任非职工代表董事共同组成公司第六届董事会，任 期自本次职工代表大会决议通过之日起至公司第六届董事会届满之日止。 经核查，吴志龙先生的任职资格和条件符合《公司法》《公司章程》和其 他相关法规关于公司职工代表董事任职的规定。吴志龙先生当选后，公司第六 届董事会成员中兼任公司高级管理人员以及由职工代表担任的董事人数总计不 超过公司董事总数的二分之一，符合相关法律法规及《公司章程》的规定。 特此公告。 ...

Industry News - Ionis announced positive topline results for its antisense oligonucleotide therapy Tryngolza (Olezarsen) in the Phase 3 Essence clinical trial, significantly reducing triglyceride levels in patients after 6 months and achieving all key secondary endpoints with statistical significance [2] Company News - Health元 announced that its subsidiary LIAN SGP plans to acquire 64.81% of Vietnamese listed company Imexpharm for approximately 15.87 million RMB, which is a leading pharmaceutical company in Vietnam with products that include antibiotics and cardiovascular drugs, showing high synergy with Health元's existing products [3] - 众生药业 reported that its subsidiary 众生睿创's innovative drug Angladiwe tablets received approval from the National Medical Products Administration, being the first global RNA polymerase PB2 protein inhibitor for treating adult patients with uncomplicated influenza A [3] - 科伦药业 announced that its subsidiary 科伦博泰's new indication application for the ADC drug sac-TMT has been accepted by CDE, aimed at treating adults with HR+ and HER2- breast cancer who have previously received endocrine therapy and other systemic treatments [3] - 艾力斯 announced that its KRASG12C inhibitor, citric acid gorasetinib tablets, has received approval from the National Medical Products Administration for treating adult patients with advanced non-small cell lung cancer with KRASG12C mutations who have received at least one systemic treatment [4]

Group 1 - The core point of the article is that Yiyigou (300937) announced that shareholders Hainan Hesen and Chengdu Heqi plan to transfer 2.469 million shares, accounting for 2.58% of the total share capital [1] - The transfer will be a non-public transfer, with the transferee being institutional investors who possess the necessary pricing capability and risk tolerance [1] - The reason for the transfer is due to the shareholders' need for funds and to improve the shareholder structure, which will help the company attract long-term institutional investors and enhance governance capabilities [1]

Core Viewpoint - 九州通 is actively expanding its strategic investments in the pharmaceutical and healthcare sectors, particularly focusing on medical aesthetics and medical devices through various initiatives and partnerships [1][2][3]. Investment Initiatives - 九州通's wholly-owned subsidiary, 九州通孵化器, has partnered with 北京楚昌私募基金 to establish a new investment fund with a total contribution of 25 million yuan, targeting investments in pharmaceuticals, medical devices, medical aesthetics, and anti-aging sectors [2][3]. - The fund's contributions include 22.99 million yuan from 九州通孵化器, accounting for 91.96% of the total, while the remaining contributions come from other partners [2]. Medical Device Expansion - 九州通 has established a new medical device supply chain company in 湖北孝感 with a registered capital of 10 million yuan, further diversifying its business operations [3]. - In the past three months, 九州通 has launched at least six new medical device companies, indicating a strong commitment to expanding its presence in the medical device sector [3]. - The medical device segment accounted for 22.32% of 九州通's total business last year, with sales revenue reaching 33.887 billion yuan in 2024, reflecting a year-on-year growth of 3.26% [3]. Medical Aesthetics Investment - 九州通 plans to invest 673 million yuan in the restructuring of 奥园美谷, acquiring 360 million shares post-restructuring, which positions the company to become a major stakeholder in the medical aesthetics market [4][6]. - 奥园美谷 has faced financial difficulties but possesses a recognized brand and customer base in the medical aesthetics sector, which 九州通 aims to leverage for growth [4]. - 九州通's medical aesthetics business achieved sales revenue of 851 million yuan in 2024, marking a significant year-on-year increase of 120.47% [4][6]. Historical Context - 九州通 has a history of investing in the medical aesthetics sector, including an early investment in 爱美客 and partnerships with other key players in the industry [5][6]. - The establishment of a dedicated medical aesthetics division and collaboration with upstream manufacturers for product development further underscores 九州通's commitment to this sector [6].

二、监事会会议审议情况 本次会议审议并通过如下议案： 经审议，监事会认为：董事会审议本次变更募集资金用途的程序符合《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等中国证监 会和深圳证券交易所规范性文件及公司《公司章程》《募集资金管理制度》等的 相关规定，公司本次变更部分募集资金用途事项，符合公司当前实际和发展需要， 有利于提高募集资金使用效率和长远利益，符合公司及全体股东的利益，不存在 损害公司、投资者特别是中小投资者利益的情形。 本议案尚需提交股东大会审议。 证券代码：301408 证券简称：华人健康 公告编号：2025-041 安徽华人健康医药股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 安徽华人健康医药股份有限公司（以下简称"公司"）第五届监事会第八次 会议已于 2025 年 5 月 16 日以书面、邮件送达形式发出通知，并于 2025 年 5 月 合相关法律法规及《公司章程》的规定，做出的决议合法有效。 经审议，监事会认为：本次使用闲置募集资金临时补充流动资金的审议程序 符合《上市公司监 ...

Group 1: Company Overview and Performance - The company operates in the pharmaceutical distribution industry, focusing on pharmaceutical commerce, warehousing, logistics, and R&D, with a marketing network covering the entire country [2] - In Q1 2025, the company achieved revenue and net profit growth, with medical devices and specialty pharmacy sales increasing by 17% and 10% year-on-year, respectively [2] - As of the end of 2024, revenue from narcotic and psychotropic products accounted for 3.75% of total income [3] Group 2: Collaboration and Market Expansion - The company is one of the national wholesale enterprises for narcotic drugs, with a sales network covering all 31 provinces, municipalities, and autonomous regions [3] - The company has accelerated collaboration with over 400 medical institutions under the China General Technology Group, having opened 102 accounts in 21 provinces, including 86 grade hospitals [4] Group 3: Strategic Responses to Market Challenges - In response to price reductions from centralized procurement and medical insurance cost control, the company aims to optimize its industrial layout and explore high-growth niche markets [5] - The company is implementing a "Five Armies" strategic plan to enhance profitability through five segments: pharmaceutical sales, medical devices, specialty pharmacies, traditional Chinese medicine, and emerging businesses [5] - Since entering the central enterprise system, the company has improved its credit and financing channels, leading to a noticeable decline in financing costs since 2024 [5] Group 4: Future Plans and Investments - The company plans to actively promote nationwide commercial network coverage under the "300 Cities" strategic plan, leveraging its scale, network, and service advantages for acquisitions and strategic partnerships in medical devices and traditional Chinese medicine [6]

Core Viewpoint - Guangzhou Pharmaceutical Co., Ltd. (referred to as "Guangzhou Medicine") will be listed on the National Equities Exchange and Quotations (NEEQ) starting May 20, 2025, after previously attempting an IPO in Hong Kong without success [1][2]. Group 1: Company Overview - Guangzhou Medicine, established in 1951, is the largest pharmaceutical distribution company in South China, engaging in wholesale and retail of pharmaceuticals, including Western medicine, traditional Chinese medicine, and medical devices, with over 1,700 employees [2]. - White Cloud Mountain Pharmaceutical Group Co., Ltd. (referred to as "White Cloud Mountain") holds a 90.92% stake in Guangzhou Medicine, making it the controlling shareholder [2]. Group 2: Financial Performance - Guangzhou Medicine's revenue for 2023 and 2024 is projected to be 52.591 billion yuan and 54.605 billion yuan, respectively, with net profits of 649 million yuan and 578 million yuan [2]. - In contrast, White Cloud Mountain reported a decline in net profit for 2024, reaching 2.835 billion yuan, a decrease of 30.09% year-on-year, with total revenue of 74.993 billion yuan, down 0.69% [4]. Group 3: Strategic Decisions - The decision to list Guangzhou Medicine on the NEEQ follows the termination of its H-share listing plans due to changes in market conditions and the expiration of regulatory approvals [2]. - White Cloud Mountain stated that the new listing will not adversely affect its financial status or operational results, as Guangzhou Medicine will remain a consolidated subsidiary [3]. Group 4: Challenges and Considerations - White Cloud Mountain's financial difficulties, including significant impairment provisions totaling approximately 471 million yuan, may impact Guangzhou Medicine's future fundraising efforts [5]. - The company faces challenges from industry policy changes and intense market competition, raising questions about its plans for product structure optimization and cost control [5].

Group 1 - Baiyunshan Holdings' subsidiary Guangzhou Pharmaceutical Co., Ltd. will be listed on the New Third Board starting May 20, 2025, marking a significant step in capital operations for Baiyunshan [1] - The listing is expected to broaden financing channels and enhance brand influence, as Guangzhou Pharmaceutical is a leading pharmaceutical distribution company in South China [1] - However, the New Third Board has relatively low liquidity, necessitating the optimization of governance structures and strengthening of profitability to attract long-term capital [1] Group 2 - Dezhan Health has signed a cooperation framework agreement with Academician Yang Baofeng to establish an academician expert workstation at its subsidiary, Deyi Pharmaceutical Co., Ltd. [2] - This collaboration aims to enhance the company's drug development capabilities in the cannabinoid innovation drug field [2] - The development of cannabinoid drugs is noted to have long cycles and strict regulations, requiring attention to clinical progress and commercialization capabilities [2] Group 3 - BeiGene has registered a Phase Ib clinical trial for BGB-16673, a BTK degrader targeting chronic spontaneous urticaria, marking it as the first autoimmune disease trial for this drug [3] - BGB-16673 is the fastest progressing BTK degrader in clinical development and has the potential to address resistance issues associated with existing BTK inhibitors [3] - The expansion into autoimmune indications opens up broader market opportunities and validates the application potential of the CDAC platform across multiple disease areas [3]

Group 1: Company Insights - Ba Tian Co., Ltd. announced a stock incentive plan, granting a total of 23 million shares, representing 2.39% of the company's total share capital, with performance targets set for 2025 and 2026 [4][5] - The company plans to expand its phosphate rock production capacity to 2.9 million tons per year, with an investment of up to 150 million RMB for the second phase of the Xiaogaozhai phosphate mine project [6] - The company is expected to achieve revenue of 5.3 billion RMB and net profit of 1.22 billion RMB in 2025, with a PE ratio of 8 times [7] Group 2: Industry Dynamics - The heavy truck market in China is expected to see a recovery in demand, with a 6% year-on-year increase in insurance registrations for heavy trucks in April 2025 [23][24] - The implementation of the old-for-new subsidy policy for heavy trucks is expected to boost sales, with 27 out of 31 provinces having announced specific subsidy application channels by mid-May 2025 [25][26] - The domestic wholesale growth rate for heavy trucks is projected to exceed 15% in 2025, driven by the old-for-new policy and a recovery in demand [26][27] Group 3: Financial Performance - Xin Jie Electric reported a revenue of 1.7 billion RMB in 2024, a year-on-year increase of 13.5%, with a net profit of 229 million RMB, up 14.84% [9][10] - Niu Wei CNC achieved a revenue of 2.462 billion RMB in 2024, with a net profit of 325 million RMB, reflecting a steady growth despite industry challenges [17][18] - JD Health reported a revenue of 16.6 billion RMB in Q1 2025, a 25.5% year-on-year increase, with adjusted net profit rising by 47.7% [45][46]

Core Viewpoint - The company reported a decline in revenue and net profit for Q1 2025, primarily due to stricter control over drug usage in medical institutions and the impact of centralized procurement policies [1][2]. Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 5.317 billion yuan, a year-on-year decrease of 7.93% [1]. - The net profit attributable to shareholders was 277 million yuan, down 7.66% year-on-year [1]. - The decline in performance was attributed to reduced drug usage by core clients in medical institutions and the impact of centralized procurement [1][2]. Group 2: Future Growth Points - The company plans to continue its strategy of collaboration across drug and medical device sectors, focusing on high-quality products and innovative projects [2]. - Emphasis will be placed on developing prescription external projects and integrating new technologies like AI to enhance retail business transformation [2]. - The company aims to strengthen its industrial segment by expanding its market presence outside the province and improving R&D capabilities [2]. Group 3: AI and Technology Integration - The "AI + Medical" service plan aims to create a comprehensive AI service system for both hospital and retail environments, enhancing supply chain efficiency and patient care [2]. - The AI assistant "A Gui Pharmacist" will provide health management services, including medication tracking and patient education [2]. Group 4: Industry Outlook - The pharmaceutical industry is expected to continue expanding due to an aging population and improvements in the healthcare system [2]. - The industry is undergoing a transformation characterized by stronger compliance, digitalization, and value-based competition [2]. Group 5: Risk Management and Financial Strategy - The company is focusing on high-quality sales and risk prevention, including measures to improve cash flow and reduce reliance on guarantees [3]. - Strategies include categorizing clients based on creditworthiness and payment capabilities to enhance sales and collection efficiency [3]. Group 6: Shareholder Engagement - The company plans to implement the profit distribution plan for 2024 within two months after approval at the shareholders' meeting [3].